{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:52:12Z","timestamp":1784976732602,"version":"3.55.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.03.024","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T11:53:11Z","timestamp":1651665191000},"page":"82-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-8917","authenticated-orcid":false,"given":"Ahmed","family":"Sayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-9212","authenticated-orcid":false,"given":"Omar M.","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-5807","authenticated-orcid":false,"given":"Omar","family":"Shazly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-1866","authenticated-orcid":false,"given":"Ahmed K.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem S.","family":"Ghaith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gerew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-1174","authenticated-orcid":false,"given":"Avirup","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-8975","authenticated-orcid":false,"given":"Michael G.","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S.","family":"Abela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.03.024_bib1","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2022.03.024_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA) extended follow-up of a 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ejca.2022.03.024_bib3","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.03.024_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.2039","article-title":"Clinical features, risk factors, and prognosis of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP like regimen","volume":"41","author":"Nakayama","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejca.2022.03.024_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018802","article-title":"Cardiotoxic effect of modern anthracycline dosing on left ventricular ejection fraction: a systematic review and meta-analysis of placebo arms from randomized controlled trials","volume":"10","author":"Jeyaprakash","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejca.2022.03.024_bib6","first-page":"871","article-title":"Cardiac outcomes in survivors of pediatric and adult cancers","volume":"32","author":"Nathan","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib7","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2021"},{"key":"10.1016\/j.ejca.2022.03.024_bib8","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2022.03.024_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib10","first-page":"49","article-title":"An overview of the bayesian approach","year":"2003","journal-title":"Bayesian Approaches to Clin Trials Heal Eval"},{"key":"10.1016\/j.ejca.2022.03.024_bib11","series-title":"GRADE handbook for grading quality of evidence and strength of recommendations","author":"Sch\u00fcnemann","year":"2013"},{"key":"10.1016\/j.ejca.2022.03.024_bib12","series-title":"A language and environment for statistical computing","author":"Team","year":"2021"},{"key":"10.1016\/j.ejca.2022.03.024_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.316.7129.469","article-title":"Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity","volume":"316","author":"Stuck","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2022.03.024_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2022.03.024_bib15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM198809223191203","article-title":"Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer","volume":"319","author":"Speyer","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.03.024_bib16","first-page":"S21","article-title":"Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin","volume":"25","author":"Elshiekh","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib17","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejca.2022.03.024_bib19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","article-title":"Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group randomized trial Pediatric Oncology Grou","volume":"34","author":"Asselin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.024_bib20","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II Receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.03.024_bib21","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Colombo","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejca.2022.03.024_bib22","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib23","first-page":"1","article-title":"Late health outcomes after dexrazoxane treatment: a report from the Children's Oncology Group","author":"Chow","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.03.024_bib24","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2147\/CMAR.S166481","article-title":"Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer","volume":"10","author":"Cochera","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2022.03.024_bib25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/etm.2011.305","article-title":"Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction","volume":"2","author":"Dess\u00ec","year":"2011","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ejca.2022.03.024_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","article-title":"Effect of enalapril on preventing anthracycline-induced cardiomyopathy","volume":"17","author":"Nabati","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.ejca.2022.03.024_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","article-title":"Preventive role of carvedilol in adriamycin-induced cardiomyopathy","volume":"144","author":"Jhorawat","year":"2016","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ejca.2022.03.024_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pbc.27308","article-title":"Role of ACE inhibitors in anthracycline-induced cardiotoxicity: a randomized, double-blind, placebo-controlled trial","volume":"65","author":"Gupta","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2022.03.024_bib29","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib30","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2022.03.024_bib31","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib32","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"key":"10.1016\/j.ejca.2022.03.024_bib34","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.21873\/anticanres.13769","article-title":"The role of metoprolol and enalapril in the prevention of doxorubicin-induced cardiotoxicity in lymphoma patients","volume":"39","author":"Georgakopoulos","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2022.03.024_bib35","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1002\/cam4.3956","article-title":"Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin","volume":"10","author":"Lee","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2022.03.024_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Asselin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.03.024_bib37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO.1998.16.1.86","article-title":"Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas","volume":"16","author":"Vici","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.024_bib38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.024_bib39","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.31557\/APJCP.2021.22.9.2847","article-title":"The role of lisinopril and bisoprolol to prevent anthracycline induced cardiotoxicity in locally advanced breast cancer patients","volume":"22","author":"Wihandono","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ejca.2022.03.024_bib40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane\u00ae) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.03.024_bib41","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in\u00a0patients with malignant hemopathies: the OVERCOME trial\u00a0(prevention of left ventricular dysfunction with enalapril\u00a0and caRvedilol in patients submitted t","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib42","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1200\/JCO.1996.14.12.3112","article-title":"Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer","volume":"14","author":"Venturini","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.024_bib43","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/MAJ.0000000000000432","article-title":"Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity","volume":"349","author":"Sun","year":"2015","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ejca.2022.03.024_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15420\/ahhj.2011.9.2.95","article-title":"Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma","volume":"9","author":"Salehi","year":"2011","journal-title":"Am Heart Hosp J"},{"key":"10.1016\/j.ejca.2022.03.024_bib45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1074248418821721","article-title":"Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial","volume":"24","author":"Nabati","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ejca.2022.03.024_bib46","first-page":"362","article-title":"Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with","volume":"14","author":"Wexler","year":"2021","journal-title":"Doxorubicin"},{"key":"10.1016\/j.ejca.2022.03.024_bib47","first-page":"47","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial","volume":"134","author":"Tashakori Beheshti","year":"2016","journal-title":"Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.33963\/KP.15163","article-title":"Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study","volume":"78","author":"S\u0142owik","year":"2020","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.ejca.2022.03.024_bib49","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.024_bib50","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Terada","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.03.024_bib51","doi-asserted-by":"crossref","DOI":"10.4143\/crt.2020.1024","article-title":"Combination of simvastatin and FAC improves response to neoadjuvant chemotherapy in advanced local breast cancer","author":"Yulian","year":"2021","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2022.03.024_bib52","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.amjcard.2018.03.194","article-title":"Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin","volume":"121","author":"Elshiekh","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40959-019-0054-5","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal","year":"2019","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.ejca.2022.03.024_bib54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-2999(01)00782-8","article-title":"Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat","volume":"414","author":"Sacco","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ejca.2022.03.024_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12947-015-0011-x","article-title":"The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity","volume":"13","author":"Akolkar","year":"2015","journal-title":"Cardiovasc Ultrasound"},{"key":"10.1016\/j.ejca.2022.03.024_bib56","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.03.024_bib57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.vph.2009.01.001","article-title":"ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat","volume":"50","author":"Sacco","year":"2009","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.ejca.2022.03.024_bib58","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1179\/1973947812Y.0000000038","article-title":"Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients","volume":"24","author":"Kang","year":"2012","journal-title":"J Chemother"},{"key":"10.1016\/j.ejca.2022.03.024_bib59","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.03.024_bib60","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2022.03.024_bib61","unstructured":"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020212 n.d."},{"key":"10.1016\/j.ejca.2022.03.024_bib62","article-title":"Statins in anthracycline-induced cardiotoxicity: rac and Rho, and the heartbreakers","volume":"8","author":"Henninger","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejca.2022.03.024_bib63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.ejca.2022.03.024_bib64","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12493","article-title":"Heart failure from cancer therapy: can we prevent it?","volume":"6","author":"Totzeck","year":"2019","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.ejca.2022.03.024_bib65","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamacardio.2019.3665","article-title":"Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat","volume":"4","author":"Mortensen","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejca.2022.03.024_bib66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.ejca.2022.03.024_bib68","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492200168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492200168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:46Z","timestamp":1760733346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492200168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":67,"alternative-id":["S095980492200168X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}